We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
Balyasny Asset Management
251
Balyasny Asset Management
Illinois
$971K +$996K +27,511 New
Truist Financial
252
Truist Financial
North Carolina
$969K +$113K +3,127 +13%
Mariner
253
Mariner
Kansas
$962K -$1.11M -30,742 -53%
FDP
254
Financiere des Professionnels
Quebec, Canada
$933K +$958K +26,456 New
PS
255
Principal Securities
Iowa
$922K +$936K +25,860 +9,438%
Allspring Global Investments
256
Allspring Global Investments
North Carolina
$897K +$5K +138 +0.6%
MML Investors Services
257
MML Investors Services
Massachusetts
$893K +$916K +25,307 New
BG
258
BDF Gestion
France
$890K -$190K -5,246 -17%
AWM
259
AE Wealth Management
Kansas
$886K -$1.05M -29,078 -54%
BPCE
260
Bank Pictet & Cie (Europe)
Germany
$882K – – –
AIM
261
AXA Investment Managers
France
$859K +$882K +24,350 New
CSP
262
Cary Street Partners
Virginia
$852K +$101K +2,785 +13%
Wealth Enhancement Advisory Services
263
Wealth Enhancement Advisory Services
Minnesota
$852K +$123K +3,394 +17%
NSEDCP
264
NJ State Employees Deferred Compensation Plan
New Jersey
$847K – – –
KRS
265
Kentucky Retirement Systems
Kentucky
$840K -$32.4K -896 -4%
M&T Bank
266
M&T Bank
New York
$813K -$99.7K -2,754 -11%
NICM
267
Neo Ivy Capital Management
New York
$797K +$818K +22,590 New
OSAM
268
O'Shaughnessy Asset Management
Connecticut
$795K +$86.8K +2,399 +12%
GIBU
269
Gulf International Bank (UK)
United Kingdom
$772K -$21.8K -602 -3%
LPC
270
Lion Point Capital
New York
$755K +$775K +21,400 New
AB
271
Amalgamated Bank
New York
$752K -$35.4K -979 -4%
SI
272
Sava Infond
Slovenia
$741K – – –
KAS
273
Kestra Advisory Services
Texas
$728K -$24.2K -669 -3%
AAM
274
Advisors Asset Management
Colorado
$701K -$3.29K -91 -0.5%
Stifel Financial
275
Stifel Financial
Missouri
$700K +$127K +3,512 +22%
9 10
11
12 13

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.